Corporation
Eli Lilly Canada Inc.
- Meetings this Parliament
- 21
- With MPs
- 6
- Since Nov 2021
- 65
- Active registrations
- 1
Most recent reported meeting: Sep 25, 2026.
Lobbying by Eli Lilly Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Sep 1, 2026
Filed by Mathilde Merlet, President and General Manager
Lobbyists
- Jill Daley · General Counsel & Vice-President Corporate Affairs
- Mathilde Merlet · President and General Manager
Institutions they may lobby: Federal Economic Development Agency for Southern Ontario (FedDev), Finance Canada (FIN), Global Affairs Canada (GAC), Great Lakes Pilotage Authority, Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Invest in Canada Hub, Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (10)Hide details
- C-64, An act respecting pharmacare - discussions around the structuring and implementation of a national pharmacare program.
- The government's economic, health, investment, science and technology, and trade policies as they relate to the pharmaceutical industry
- Pharmaceutical pricing policy arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
- Pharmaceutical and trade policy as it relates to security of supply for Canadian medicines.
- Patented Medicines Pricing Review Board (PMPRB) – regulations that can impact the Canadian pharmaceutical industry.
- Patented Medicine Notice of Compliance (PMNOC) Regulations - enforcement of Intellectual Property with respect to the Canadian pharmaceutical industry.
- Patent Act - An Act respecting patents of invention with regard to Intellectual Property Protection for pharmaceutical products - federal court decisions that have changed the disclosure requirements regarding the utility of an invention.
- Intellectual Property - Changes to Patented Medicine (Notice of Compliance) (PMNOC) regulations - important regulations that can affect Eli Lilly Canada's business
- Free trade treaty agreement as it relates to the North American Free Trade Agreement (NAFTA) and free trade negotiations as it relates to Columbia, India, and the European Union
- Food and Drug Act - An Act respecting food, drugs, cosmetics and therapeutic devices. Discussions relating to progressive licensing and the modernization of the Food and Drug Act.
Registration 960985-6034-39. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Kenneth L Custer (25), Mathilde Merlet (21), Rhonda Pacheco (19).
-
Reported by Kenneth L Custer · In-house (corporation)
- Helena Jaczek · Member of Parliament
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Yasir Naqvi · Member of Parliament
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Arun Alexander · Deputy Head of Mission, Global Affairs Canada (GAC)
Industry
-
Reported by Kenneth L Custer · In-house (corporation)
- Judith Seidman · Senator, Senate of Canada
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Michelle Boudreau · Executive Director, Health Canada (HC)
- Daniel MacDonald · Director General, Drugs for Rare Diseases, Health Canada (HC)
- Bobby Chauhan · Director, Health Canada (HC)
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Paul Brogan · Market Director, Invest in Canada Hub
- Harold Dremin · Chief Investor Services Officer, Invest in Canada Hub
HealthIndustry
-
Reported by Kenneth L Custer · In-house (corporation)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
- Laura Stokes · Policy Analyst, Innovation, Science and Economic Development Canada (ISED)
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Jade Mallette · Director of Parliamentary Affairs, Health Canada (HC)
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Connor MacDonald · Policy Advisor, House of Commons
- Bryce McRae · Manager of Stakeholder Relations, House of Commons
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Yash Nanda · Policy Advisor, Finance Canada (FIN)
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Erin Campbell · Director, Innovation, Science and Economic Development Canada (ISED)
- Paul Brogan · Market Director, Invest in Canada Hub
- David Lee · Chief Regulatory Officer, Health Canada (HC)
- Anne Bowes · Director, Health Canada (HC)
and 1 moreShow fewer
- Michelle Ciesielski · Manager, Office of Patented Medicines and Liaison, Health Canada (HC)
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Loris Mirella · Director, Global Affairs Canada (GAC)
- David Norris · Senior Trade Policy Officer, Global Affairs Canada (GAC)
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
- Caroline Menard · Manager, Innovation, Science and Economic Development Canada (ISED)
- Benoit Leduc · Manager, Innovation, Science and Economic Development Canada (ISED)
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Yash Nanda · Policy Advisor, Finance Canada (FIN)
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Eshan Naik · Director of Policy, Health Canada (HC)
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Paul Brogan · Market Director, Invest in Canada Hub
- Abbigael Loomis · Investor Services Associate, Invest in Canada Hub
Economic Development
-
Reported by Kenneth L Custer · In-house (corporation)
- Eshan Naik · Director of Policy, Health Canada (HC)
- Ophelia John · Senior Policy Advisor, Health Canada (HC)
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Eshan Naik · Director of Policy, Health Canada (HC)
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Stefania Trombetti · Assistant Deputy Minister, Health Canada (HC)
- Greg Loyst · Director General, Health Canada (HC)
- Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
- Marie-Elisabeth Lebrun · Director, Health Canada (HC)
Health
-
Reported by Kenneth L Custer · In-house (corporation)
- Melissa Lantsman · Member of Parliament
Health
-
Reported by Rhonda Pacheco · In-house (corporation)
- Simon Kennedy · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Eric Costen · Senior Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Eric Belair · Associate Assistant Deputy Minister, Health Canada (HC)
- Suzanne McGurn · President and CEO, Health Canada (HC)
Health
-
Reported by Rhonda Pacheco · In-house (corporation)
- Kyle Seeback · Member of Parliament
- Ben Martin · Member's Assistant, House of Commons
International Trade
-
Reported by Rhonda Pacheco · In-house (corporation)
- Darryl Patterson · Departmental Liaison Advisor, Innovation, Science and Economic Development Canada (ISED)
- Samir Chhabra · Officer, Innovation, Science and Economic Development Canada (ISED)
- Benoit Leduc · Manager, Innovation, Science and Economic Development Canada (ISED)
- Kasondra White · Director, Innovation, Science and Economic Development Canada (ISED)
International Trade
-
Reported by Rhonda Pacheco · In-house (corporation)
- Loris Mirella · Director, Global Affairs Canada (GAC)
- Clarissa Allen · Trade Policy Officer, Global Affairs Canada (GAC)
- Nicolas Lesieur · Senior Trade Policy Officer, Global Affairs Canada (GAC)
International Trade
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.